Kalaris Therapeutics, Inc. (KLRS) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Kalaris Therapeutics reported revenue of $0. Net income was -$43.4M, or -$2.85 per diluted share. Operating activities generated -$38.4M of cash, leaving -$38.6M of free cash flow. At fiscal year end, Kalaris Therapeutics held $121.7M in total assets against $42.9M in total liabilities, including $98.1M of cash and equivalents.
Open the full interactive Kalaris Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Kalaris Therapeutics Key Stats
| Share Price | $2.23 |
|---|---|
| Market Cap | $53.1M |
| 52-Week Range | $2.23 – $10.98 |
| Shares Outstanding | 23.8 million (basic, 2026 Q2) |
Kalaris Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$71.3M | -$169.8M | -$171.2M | -$199.9M | -$65.4M | -$46.2M |
| Pre-Tax Income | -$69.8M | -$171.0M | -$169.0M | -$190.5M | -$58.8M | -$43.4M |
| Income Tax | — | $1.0M | -$265,000 | -$126,000 | $0 | $0 |
| Net Income | -$69.8M | -$172.0M | -$168.7M | -$190.4M | -$58.8M | -$43.4M |
| Diluted EPS | -$59.57 | -$63.02 | -$50.60 | -$42.09 | -$11.73 | -$2.85 |
Kalaris Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$11.9M | -$10.0M | -$10.9M | -$11.5M |
| Diluted EPS | -$0.64 | -$0.65 | -$0.46 | -$0.48 |
Kalaris Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $122.7M | $201.7M | $106.1M | $90.1M | $118.3M | $98.1M |
| Current Assets | $361.3M | $253.3M | $243.1M | $187.6M | $118.5M | $118.8M |
| Total Assets | $370.8M | $286.6M | $277.1M | $190.8M | $118.5M | $121.7M |
| Current Liabilities | $12.3M | $37.9M | $24.3M | $28.4M | $5.2M | $9.7M |
| Total Liabilities | $17.8M | $61.3M | $52.6M | $45.0M | $5.2M | $42.9M |
| Shareholders' Equity | $353.1M | $225.3M | $224.5M | $145.8M | $113.3M | $78.8M |
Kalaris Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$60.8M | -$106.3M | -$142.1M | -$124.5M | -$67.7M | -$38.4M |
| Cash From Investing | -$169.5M | $186.0M | -$80.5M | $38.0M | $95.0M | -$19.7M |
| Cash From Financing | $292.0M | $232,000 | $127.0M | $70.5M | $21,000 | $155.0M |
| Free Cash Flow | -$61.0M | -$106.3M | -$142.1M | — | — | -$38.6M |
Figures from Kalaris Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Kalaris Therapeutics financials page for every line item.
Kalaris Therapeutics Company Profile
| Ticker | KLRS |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Berkeley Heights, New Jersey |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001754068 |
Frequently Asked Questions
What was Kalaris Therapeutics' revenue in fiscal 2025?
Kalaris Therapeutics (KLRS) reported revenue of $0 for fiscal 2025.
What is Kalaris Therapeutics' annual revenue history?
Kalaris Therapeutics' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Kalaris Therapeutics' net income in fiscal 2025?
Kalaris Therapeutics reported net income of -$43.4M for fiscal 2025.
What was Kalaris Therapeutics' earnings per share (EPS) in fiscal 2025?
Kalaris Therapeutics' diluted EPS was -$2.85 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Kalaris Therapeutics generate in fiscal 2025?
Kalaris Therapeutics generated -$38.6M of free cash flow in fiscal 2025.
What was Kalaris Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Kalaris Therapeutics reported revenue of $0.
How many shares of Kalaris Therapeutics are outstanding?
Kalaris Therapeutics reported a weighted average of 23.8 million basic shares outstanding in 2026 Q2.
What is Kalaris Therapeutics' market cap?
Based on its latest closing price, Kalaris Therapeutics (KLRS) has a market capitalization of about $53.1M.
When does Kalaris Therapeutics' fiscal year end?
Kalaris Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Kalaris Therapeutics headquartered?
Kalaris Therapeutics lists its business address in Berkeley Heights, New Jersey in its SEC filings.
Kalaris Therapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →